Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition notifications and does not contain financial performance data.
Material Changes
No material changes to financial performance or business operations are reported in this filing. The document details administrative updates to notional share interests for specific executives following the re-investment of dividends paid on April 11, 2013.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It strictly reports on the acquisition of Ordinary Shares and American Depositary Shares (ADSs) under the personal and matching contribution elements of the Deferred Annual Bonus Plan for the following individuals:
- Sir Andrew Witty
- Mr S Dingemans
- Dr M M Slaoui
- Mr R G Connor
- Mr W C Louv
- Mr D S Redfern
- Mr P C Thomson
- Mr D E Troy
- Dr P J T Vallance
- Ms E Walmsley
The notional price used for these transactions was 1549.50 pence per Ordinary Share and $47.75 per ADS.
Investor Verification Checklist
- Verify the total number of shares acquired by each named executive under the 2009 Deferred Annual Bonus Plan.
- Confirm the vesting schedule and measurement period for the notional dividends accrued.
- Review the company's Form 20-F for comprehensive financial data, as this Form 6-K contains no financial statements.